Sclerostin: therapeutic horizons based upon its actions. - Wikidata - wikimedia - TriplyDB

Sclerostin: therapeutic horizons based upon its actions.

Sclerostin: therapeutic horizons based upon its actions.

http://www.wikidata.org/entity/Q37974871

about

Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges Impact of inflammation on the osteoblast in rheumatic diseases A review of denosumab for the treatment of osteoporosis A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density Parathyroid hormone: anabolic and catabolic actions on the skeleton The swaying mouse as a model of osteogenesis imperfecta caused by WNT1 mutations The neurobiology of skeletal pain Estrogen via estrogen receptor beta partially inhibits mandibular condylar cartilage growth.Wnt signaling and the control of human stem cell fate.Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels Romosozumab for the treatment of osteoporosis.Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis.PTH Signaling and Epigenetic Control of Bone Remodeling.Osteoporosis - a current view of pharmacological prevention and treatment Mechanisms of multiple myeloma bone disease.Stem cell signaling as a target for novel drug discovery: recent progress in the WNT and Hedgehog pathways.Wnt Signaling and Its Contribution to Craniofacial Tissue Homeostasis.Osteocytic signalling pathways as therapeutic targets for bone fragility.Connecting Bone and Fat: The Potential Role for Sclerostin.The effect of dried plum on serum levels of receptor activator of NF-κB ligand, osteoprotegerin and sclerostin in osteopenic postmenopausal women: a randomised controlled trial.Levels of serum sclerostin, metabolic parameters, and periodontitis in -postmenopausal women with diabetes.Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity.Genetic association study of Dickkopf-1 and sclerostin genes with paget disease of bone.Serum sclerostin is decreased following vitamin D treatment in young vitamin D-deficient female adults.Myeloma bone disease: Pathophysiology and management.

P2860

Q26744599-366645C3-D6E2-47D5-A31B-818F43059DB2 Q26829246-431EC9C4-6DC9-4901-86DD-062124031015 Q27005894-8A715460-9F06-4124-8F5F-E349672801CD Q28247445-D02C4F38-6459-4AD2-BEA8-DCA8865261E6 Q33609126-E7EFE246-456F-4CD1-8DCB-8F9E4A738CFF Q33847609-4091E9C1-59A9-4481-85B1-8A91C53E3590 Q34402192-D4A38387-4383-43F9-8F31-1BDBA89C808D Q34616981-F8576494-355F-48E7-A0CD-465568A2A60D Q34658275-DC65B175-FD30-4235-A018-C05B1C13ECA0 Q34661015-1CFB61F7-139C-4F4F-B20C-F86C85EA548F Q34680463-6BC4B96A-3454-4385-987E-DA34CBF9869F Q35694436-3AB7C35B-2068-470F-8D31-72DD8315FD1D Q36858233-ADD83F60-EEE8-49DD-B918-A3227FB44A58 Q36939677-E0BA26CF-C06B-4BBC-A1C0-6CF0E4412966 Q37056408-A593AF12-0B13-4CA7-813C-709AE22D8B08 Q38109501-EC12C7B2-A7A2-44B0-A487-DB1986B5D2A9 Q38569131-E0E928E8-2327-4B5D-AEFF-70E7A1BB9907 Q38845640-F7E09188-51B6-4841-B848-8F8992283DA8 Q39350147-84F74974-2536-40C4-AF40-015893390AE4 Q46125695-40A5E1FF-1DD9-4AB9-BF18-AD91858D787C Q47384432-6D97B2B1-5D68-4847-8E38-85B73BA2C420 Q47894997-1FE807BE-15B5-4BFF-A138-45E9E9FEC085 Q50850956-00115272-6C7A-48EE-9A8A-B500C01F001B Q51022133-E457350B-AD67-4C06-9DC3-A0BECA48C2DF Q55209965-3CCE1DB6-C6FA-4479-8657-CFF29C9D90F7

P2860

Sclerostin: therapeutic horizons based upon its actions.

http://www.wikidata.org/entity/Q37974871

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Sclerostin: therapeutic horizons based upon its actions.

@en

Sclerostin: therapeutic horizons based upon its actions.

@nl

type

label

Sclerostin: therapeutic horizons based upon its actions.

@en

Sclerostin: therapeutic horizons based upon its actions.

@nl

prefLabel

Sclerostin: therapeutic horizons based upon its actions.

@en

Sclerostin: therapeutic horizons based upon its actions.

@nl

P1433

Q37974871-CDC8FE8C-302B-4D2E-A467-697265A3F945

P1476

Q37974871-F018DD43-043A-48A1-8304-C0318B38271D

P2093

Q37974871-2210C805-D937-4223-B4F9-0BBE1D9BBCF6

P2860

Q37974871-02CF88AF-B157-4497-AEAE-F52B52788E14

Q37974871-0AB09D97-D877-45F8-8DB2-4DE1DC0B25BC

Q37974871-18AD5D12-FF3F-4E01-85FB-CD64F531DCB8

Q37974871-1AE797D9-35E3-4B20-9AC1-DAC9D84F65CE

Q37974871-1D174EDF-ACB0-45F0-A492-4F1E098C6660

Q37974871-1FEBC5C3-BA90-4018-BCA5-AFB8A134BBB8

Q37974871-20CBB7AF-A639-4920-9FA6-4F680688596E

Q37974871-2214D7C2-F6D2-4F64-A21F-D03CE3133683

Q37974871-2FC939ED-A39C-4452-865F-AA361BF0EC9F

Q37974871-30EF1E2C-3690-4F53-A4AF-2246795394F5

P2888

Q37974871-C007DE1C-7C13-4E6A-A3FD-1E4700D1712A

P304

Q37974871-7ADC35B1-D688-4AF6-BC93-057662B6392E

P31

Q37974871-853E308B-4002-46D7-A7B2-B2EEA3F25C01

P356

Q37974871-C107DAEC-275D-4AF6-A90B-007C36FB2062

P433

Q37974871-CF4279F8-A68B-4249-9C2A-1CC01F6FCADE

P478

Q37974871-83792A8F-3683-4494-A4C6-D817E241841A

P50

Q37974871-8FDABF62-A1A5-43BB-A4BE-F409D9A288BB

P577

Q37974871-513BC493-2438-41A2-9192-F1837AD3E08B

P698

Q37974871-FF323FA0-E14B-4B21-8CD7-F9379A029A8E

P356

S11914-011-0089-5

P1433

Current osteoporosis reports

P1476

Sclerostin: therapeutic horizons based upon its actions.

@en

P2093

Aline G Costa

http://www.w3.org/2001/XMLSchema#string

P2860

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor

Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein

Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways

Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist

Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease

Characterization of the Structural Features and Interactions of Sclerostin: MOLECULAR INSIGHT INTO A KEY REGULATOR OF Wnt-MEDIATED BONE FORMATION

A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population

Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling

P2888

s11914-011-0089-5

P304

64-72

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11914-011-0089-5

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

John P. Bilezikian

P577

2012-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22234741

http://www.w3.org/2001/XMLSchema#string